Id-1 regulates Bcl-2 and Bax expression through p53 and NF-κB in MCF-7 breast cancer cells

Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, Srivastava G, Wong YC, Wang X, Chan KW (2007) Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 97:1409–1415

Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X (2004) Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25:881–887

Fong S, Debs RJ, Desprez PY (2004) Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 10:387–392

Lasorella A, Uo T, Iavarone A (2001) Id proteins at the cross-road of development and cancer. Oncogene 20:8326–8333

Ling MT, Wang X, Zhang X, Wong YC (2006) The multiple roles of Id-1 in cancer progression. Differentiation 74:481–487

Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R, Massague J (2007) ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 104:19506–19511

Forootan SS, Wong YC, Dodson A, Wang X, Lin K, Smith PH, Foster CS, Ke Y (2007) Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer. Hum Pathol 38:1321–1329

Li X, Zhang Z, Xin D, Chua CW, Wong YC, Leung SC, Na Y, Wang X (2007) Prognostic significance of Id-1 and its association with EGFR in renal cell cancer. Histopathology 50:484–490

Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, Richards PC, Bennington JL, Lee NM, Debs RJ, Desprez PY (2003) Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA 100:13543–13548

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

Zhang X, Ling MT, Wang X, Wong YC (2006) Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 118:2072–2081

Zhang X, Ling MT, Wong YC, Wang X (2007) Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci 98:308–314

Zhang X, Ling MT, Wang Q, Lau CK, Leung SC, Lee TK, Cheung AL, Wong YC, Wang X (2007) Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 282:33284–33294

Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153–164

Malaguarnera L (2004) Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 23:367–387

Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619

Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967–969

Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Buchler MW (1998) BAX, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43:414–421

Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16:2583–2590

Reed JC (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34:9–19

Yin XM, Oltvai ZN, Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321–323

Yin DX, Schimke RT (1996) Inhibition of apoptosis by overexpressing Bcl-2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Proc Natl Acad Sci USA 93:3394–3398

Harigai M, Miyashita T, Hanada M, Reed JC (1996) A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Oncogene 12:1369–1374

Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM (1985) Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315:340–343

Levine AJ (1997) P53, the cellular gatekeeper for growth and division. Cell 88:323–331

Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V (2007) Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 13:192–199

Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095–2097

Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS (1999) P53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 274:15237–15244

Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3131–3135

Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299

Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed JC, Merville MP, Bours V (2001) Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 20:2805–2813

Heckman CA, Mehew JW, Boxer LM (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898–3908

Sohur US, Dixit MN, Chen CL, Byrom MW, Kerr LA (1999) Rel/NF-kappaB represses bcl-2 transcription in pro-B lymphocytes. Gene Expr 8:219–229

Hui CM, Cheung PY, Ling MT, Tsao SW, Wang X, Wong YC, Cheung AL (2006) Id-1 promotes proliferation of p53-deficient esophageal cancer cells. Int J Cancer 119:508–514

Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC (2003) Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22:4498–4508

Kim HJ, Chung H, Yoo YG, Kim H, Lee JY, Lee MO, Kong G (2007) Inhibitor of DNA Binding 1 Activates Vascular Endothelial Growth Factor through Enhancing the Stability and Activity of Hypoxia-Inducible Factor-1{alpha}. Mol Cancer Res 5:321–329

Bostik P, Dodd GL, Villinger F, Mayne AE, Ansari AA (2004) Dysregulation of the polo-like kinase pathway in CD4+ T cells is characteristic of pathogenic simian immunodeficiency virus infection. J Virol 78:1464–1472

Choi BY, Kim HY, Lee KH, Cho YH, Kong G (1999) Clofilium, a potassium channel blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Cancer Lett 147:85–93

Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446:475–482

Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310

Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10:431–442

Steele RJ, Lane DP (2005) P53 in cancer: a paradigm for modern management of cancer. Surgeon 3:197–205

Ritchie A, Gotoh A, Gaddy J, Braun SE, Broxmeyer HE (1997) Thrombopoietin upregulates the promoter conformation of p53 in a proliferation-independent manner coincident with a decreased expression of Bax: potential mechanisms for survival enhancing effects. Blood 90:4394–4402

Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327–2334

Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K (1990) Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 10:561–568

Zhang YH, Lin JX, Vilcek J (1990) Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol Cell Biol 10:3818–3823

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med 324:1–8

Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC, Cheung AL (2007) Id-1 activation of PI3K/Akt/NF{kappa}B signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 28:2313–2320

Wilson JW, Deed RW, Inoue T, Balzi M, Becciolini A, Faraoni P, Potten CS, Norton JD (2001) Expression of Id helix–loop–helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res 61:8803–8810

Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW (2005) Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 65:375–389

McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6:2921–2927